Investigational Drug Information for TT-00420
✉ Email this page to a colleague
What is the drug development status for TT-00420?
TT-00420 is an investigational drug.
There have been 9 clinical trials for TT-00420.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2026.
The most common disease conditions in clinical trials are Cholangiocarcinoma, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are TransThera Sciences (Nanjing), Inc., TransThera Biosciences Co., Ltd, and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.
There are three US patents protecting this investigational drug.
Summary for TT-00420
| US Patents | 3 |
| International Patents | 0 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2026-01-01) |
| Vendors | 17 |
Recent Clinical Trials for TT-00420
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | TransThera Sciences (Nanjing), Inc. | PHASE3 |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | TransThera Sciences | PHASE1 |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Memorial Sloan Kettering Cancer Center | PHASE1 |
Clinical Trial Summary for TT-00420
Top disease conditions for TT-00420
Top clinical trial sponsors for TT-00420
US Patents for TT-00420
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TT-00420 | ⤷ Start Trial | Multi-kinase inhibitor compound, and crystal form and use thereof | Transthera Sciences Nanjing Inc | ⤷ Start Trial |
| TT-00420 | ⤷ Start Trial | Multi-kinase inhibitor compound, and crystal form and use thereof | Transthera Sciences Nanjing Inc | ⤷ Start Trial |
| TT-00420 | ⤷ Start Trial | Method for treating a cancer mediated by abnormality of multi-kinases | Transthera Sciences Nanjing Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
